Another exec departs troubled Endo--and this time, it's for another drugmaker

Endo

Endo’s ($ENDP) CEO exodus is continuing. Its CFO is following its CEO out the door--to work for another drugmaker, no less.

Thursday, the Dublin company announced that financial chief, Suketu Upadhyay, would be hitting the road to “assume a senior-level finance position at a global biopharmaceutical company.” Blaise Coleman, Endo's SVP of Global Finance Operations, will step up in his stead while Endo searches for a permanent replacement.

It’s been a rocky financial year for Endo, which--much like Valeant ($VRX), a company whose footsteps it’s seemingly been following in for years--slashed its Q2 guidance earlier this year, and the 40% share-price decline that ensued locked up the stock’s second-worse daily performance ever. It also cut 740 jobs. The company blamed new rivals on the market, greater-than-expected generics price erosion, regulatory delays and more for a revised revenue forecast that hit well below analyst expectations.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

But new Endo skipper Paul Campanelli--the former Par chief who relieved Endo’s Rajiv De Silva late last month--was quick to point out that the company recently reaffirmed its third-quarter and full-year predictions, an attempt to reassure investors that more bad news wasn’t on the way.

What may be on the way for the troubled drugmaker, though? Divestments. Late in June, Reuters reported that Endo--like Valeant--was looking for asset sales that could help pay down its acquisition-fueled debt mountain.  And Thursday, Campanelli noted that the specialty pharma would “complete a product-by-product assessment of our portfolio and further sharpen Endo's strategy and operational focus."

And analysts are already talking up potential takers. Earlier this week, RBC Capital Markets’ Randall Stanicky wrote in a note to investors that Endo’s pain business could make a good buy for California’s Depomed ($DEPO), which may scout for M&A now that it’s settled a proxy dispute with activist investor Starboard Value.

- read Endo's release

Special Report: The most influential people in biopharma today - 2014 - J. Michael Pearson - Valeant

Related Articles:
Depomed strikes unexpected deal with activist Starboard, adding J&J, Abbott vets to board
It's out with the old CEO, in with the new as Endo's Campanelli takes De Silva's seat
Endo keeps up its Valeant act with asset-sale talks
Endo's Valeant-esque guidance-slashing decimates shares
Valeant investors, shocked by lightweight guidance, aren't buying CEO Pearson's recovery plans
Endo scoops up Par Pharma for $8B to gain ground in injectables
Is Endo on the verge of a Valeant-type acquisition binge?

Read more on

Suggested Articles

With a brand new approval for Adakveo under its belt, Novartis Sunday flaunted an analysis showing the drug could cut patient hospitalizations by 40%.

BeiGene only just won its first Brukinsa nod in MCL. But it’s already pushing to join the CLL field, and Sunday it rolled out more data.

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.